A carregar...
Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer
SRC tyrosine kinase is frequently overexpressed and activated in late-stage, poor prognosis ovarian tumours, and preclinical studies have supported the use of targeted SRC inhibitors in the treatment of this disease. The SAPPROC trial investigated the addition of the SRC inhibitor saracatinib (AZD05...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5797008/ https://ncbi.nlm.nih.gov/pubmed/29435137 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23524 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|